Loading...

Lepu Biopharma Co., Ltd.

2157.HKHKSE
Healthcare
Biotechnology
HK$9.19
HK$1.24(15.60%)

Lepu Biopharma Co., Ltd. (2157.HK) Stock Competitors & Peer Comparison

See (2157.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2157.HKHK$9.19+15.60%15B-32.00-HK$0.26N/A
1801.HKHK$97.65+5.00%158.8B-1327.14-HK$0.07N/A
9926.HKHK$159.60+2.11%136.3B-230.45-HK$0.66N/A
1177.HKHK$7.46+1.91%129.7B65.91HK$0.11+0.97%
2269.HKHK$31.50+0.48%127B36.73HK$0.85N/A
1530.HKHK$31.72+5.03%72.9B32.77HK$0.93+0.82%
3759.HKHK$22.18+1.74%56.1B18.92HK$1.15+1.10%
6821.HKHK$104.30+2.56%41.6B33.70HK$3.08+1.16%
1877.HKHK$26.82+9.25%37.4B-16.94-HK$1.42N/A
1548.HKHK$17.29+4.16%37B-26.81-HK$0.64N/A
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2157.HK vs 1801.HK Comparison August 2025

2157.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2157.HK stands at 15B. In comparison, 1801.HK has a market cap of 158.8B. Regarding current trading prices, 2157.HK is priced at HK$9.19, while 1801.HK trades at HK$97.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2157.HK currently has a P/E ratio of -32.00, whereas 1801.HK's P/E ratio is -1327.14. In terms of profitability, 2157.HK's ROE is -0.51%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 2157.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2157.HK.Check 1801.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;